文献速递临床试验与 GCP

评估载有5%氯沙坦钾的醇质体凝胶治疗人瘢痕疙瘩疗效的随机临床试验研究:试验方案

A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel to treat human keloids: a trial protocol.
PubMed 文献 · Trials · 2024-01-02

本随机临床试验将46名成人瘢痕疙瘩患者分为两组,每组23人,分别接受5%氯沙坦钾醇质体凝胶或病灶内注射10%曲安奈德治疗。在12周内于基线、4周、8周和12周四个时间点测量POSAS 3.0评分、红斑与色素沉着程度、表面积、厚度和柔韧性变化,以评估疗效。

要点

  • 5%氯沙坦钾醇质体凝胶与10%曲安奈德病灶内注射进行随机对照比较。
  • 每组23名成人瘢痕疙瘩患者,共46人。
  • 主要观察指标包括POSAS 3.0评分、红斑、色素沉着、表面积、厚度和柔韧性。

核心结论

  • 本研究旨在评估5%氯沙坦钾醇质体凝胶治疗人瘢痕疙瘩的疗效。

研究设计与样本

  • 随机临床试验,纳入46名成人瘢痕疙瘩患者,分为两组,每组23人。
  • 一组接受5%氯沙坦钾醇质体凝胶,另一组接受病灶内注射10%曲安奈德。
  • 在12周内于基线、4周、8周和12周四个时间点进行测量。

主要发现

  • 原文未报告结果。

关键数值与推荐

  • 使用POSAS 3.0评分评估瘢痕疙瘩。
  • 测量红斑程度、色素沉着程度、表面积、厚度和柔韧性。
  • 统计学分析使用SPSS软件24版,显著性水平为p < 0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Keloid is a skin disorder that results from excessive fibrous tissue growth in the area of the initial trauma. Treating keloids can be challenging since the success of various treatments varies from one study to another. Triamcinolone acetonide injection, a standard treatment, can cause undesirable side effects. Meanwhile, the effectiveness of existing topical therapies for keloids is not always reliable. The pro-inflammatory, pro-proliferative, and pro-fibrotic effects of angiotensin II in human skin contribute to keloid formation. Losartan potassium, an angiotensin II blocker, has the potential to act as an anti-keloid agent. Due to the thicker skin structure of a keloid and ease of application, ethosome gel is chosen as a safe and comfortable carrier for losartan potassium, making it a good choice for treating keloids. METHODS: In this randomised clinical trial, 46 adults with keloids were divided into two treatment groups. One group of 23 participants received 5% losartan potassium loaded in ethosomal gel, while the other group of 23 participants received intralesional injections of 10% triamcinolone acetonide. Over 12 weeks, changes in POSAS 3.0 scores, degree of erythema and pigmentation, surface area, thickness, and pliability of the keloids will be measured at four different times: baseline, 4 weeks, 8 weeks, and 12 weeks. Statistical analysis will be conducted using SPSS software version 24, with a significance level of p < 0.05. DISCUSSION: Losartan potassium is believed to be beneficial for keloid management because it inhibits the angiotensin II receptor, which plays a role in inflammation, proliferation, and fibrosis. This study examines the efficacy of 5% losartan potassium loaded in ethosomal gel for human keloids. TRIAL REGISTRATION: Clinicaltrial.gov identifier NCT05893108 . Registered on 7 June 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Anggraini YE, Trisnowati N, Martien R, et al. A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel to treat human keloids: a trial protocol. Trials. 2024. PMID: 38167064. doi:10.1186/s13063-023-07880-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。